Acadia Pharmaceuticals Inc. has announced plans to initiate several new clinical studies as part of its expanding pipeline strategy. The company will begin a Phase 2 study for ACP-204 in Lewy Body Dementia Psychosis (LBDP) and a Phase 3 study in Japan for trofinetide in Rett syndrome, both scheduled for the third quarter of 2025. Additionally, early in the fourth quarter of 2025, Acadia will present topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome following the recent completion of enrollment. These developments are part of Acadia's broader initiative to advance care in neurological and rare diseases, with multiple study readouts anticipated by the end of 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.